Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Narendranath Epperla, Babatunde Adedokun, Hamza Hashmi, Mazyar Shadman, Allison Marie Winter, Alex Francisco Herrera, Mehdi Hamadani, Caron Jacobson, Nausheen Ahmed, Waleska Perez, Zhongyu Feng, Kenny Hu, Brad Du, Jenny Kim, Timothy Best, Anjani Baer, Arjana Pradhan, Marcelo C. Pasquini, Sairah Ahmed
Institutions: Huntsman Cancer Institute, Kite (United States), Memorial Sloan Kettering Cancer Center, Fred Hutch Cancer Center, Cleveland Clinic, City Of Hope National Medical Center, Medical College of Wisconsin, Dana-Farber Cancer Institute, University of Kansas Medical Center, The University of Texas MD Anderson Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4410818819